May 24th, 2004

clifton mining company (CFTN)

Alpine, Utah

May 24, 2005

FORM 10-SB AND LARGEST SINGLE ORDER TO DATE

In the context of our ongoing efforts to become a fully reporting issuer the Company withdrew its Form 10-SB Registration Statement on Friday in order to complete an appraisal on the Company’s mining claims and to obtain the cost estimates as required by SFAS No. 143 for future Asset Retirement Obligations.

The Company will re-submit the Form 10-SB Registration Statement as soon as the appraisal on the claims and the cost estimate for asset retirement is completed and incorporated into the Registration Statement.

We enjoyed visiting with many of you at our shareholders’ meeting.  We also appreciate your support as evidenced by the 82% common shareholder voting turnout.  Both Mr. William Moeller and Mr. Murray Nye each received a 99% approval from the voting shareholders to continue as board members.

American Biotech Labs (ABL) a private company in which Clifton Mining Company is the largest individual shareholder, has received its largest single order to date of 70,000 bottles of product.  To date, ABL’s orders are substantially ahead of last years.  ABL is also continuing its efforts on Malaria as reported in its April 26, 2005 Congressional Testimony to Chairman Smith’s Committee on International Relations located at (http://wwwc.house.gov/international_relations/109/moe042605.pdf).

Clifton trades on the U.S. OTC: (CFTN).  For additional information, contact Dr. Ken Friedman, President at 303-642-0659 or Keith Moeller Vice President at 801-756-1414 or see our website at www.cliftonmining.com.

###

Note: Any statements released by Clifton Mining Company that are forward looking are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Editors and investors are cautioned that forward looking statements invoke risk and uncertainties that may affect the company’s business prospects and performance.  These include economic, competitive, governmental, technological and other factors discussed in the company’s business plan and due-diligence information.